Trial Profile
A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 01 Aug 2023 Planned primary completion date changed from 14 May 2025 to 20 Jan 2025.
- 12 Feb 2021 Planned number of patients changed from 93 to 101.
- 12 Feb 2021 Planned primary completion date changed from 5 Mar 2025 to 14 May 2025.